Send to

Choose Destination
Future Oncol. 2019 Jun;15(17):1989-1995. doi: 10.2217/fon-2019-0001. Epub 2019 Jun 7.

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Author information

Department of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.


Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.


10-day decitabine; acute myeloid leukemia; frail patients; hypomethylating agents; older adults; overall survival


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center